While there was no detectable Oct-4 and Nanog expression in non-tumor breast tissues, 41.27% of breast cancer samples were positive for Oct-4, 36.51% were positive Nanog, and 20% were positive for both Oct-4 and Nanog. Here, NANOG is linked to breast carcinoma.